company background image
JNJ logo

Johnson & Johnson NYSE:JNJ Stock Report

Last Price

US$155.17

Market Cap

US$373.6b

7D

0.8%

1Y

1.8%

Updated

24 Nov, 2024

Data

Company Financials +

Johnson & Johnson

NYSE:JNJ Stock Report

Market Cap: US$373.6b

JNJ Stock Overview

Researches, develops, manufactures, and sells various products in the healthcare field worldwide. More details

JNJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance3/6
Financial Health4/6
Dividends5/6

Rewards

Trading at 41.9% below our estimate of its fair value

Earnings are forecast to grow 10.63% per year

Pays a reliable dividend of 3.2%

Risk Analysis

Large one-off items impacting financial results


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Innovation And Decisive Expansion Propel Growth In High-Potential Markets

Key Takeaways Recent acquisitions and new product launches in MedTech and Innovative Medicine are poised to drive future revenue growth and market expansion. Strategic focus on high-innovation areas is expected to boost operational efficiencies and improve earnings and net margins.
View narrative
US$174.89
FV
11.3% undervalued intrinsic discount
3.33%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
4 days ago author updated this narrative
GO
Goran_Damchevski
Equity Analyst

Rich Drug Pipeline Will Push Revenues and Earnings Higher

Key Takeaways Well-diversified drug pipeline with 52 drugs in late-stage approval - a good hedge for its patent expirations Kenvue spin off allows JNJ to focus on its more profitable Medical Devices and Pharmaceuticals segments Continued dividend increases and buybacks are affordable and will help capital returns Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins Some risks around litigation, patent expiry and drug success are present Catalysts Robust Drug Pipeline: 52 Drugs Racing To The Finish Line In Late-Stage Approval The key threat to a pharmaceutical stock is the patent expiration of their high value assets. Should a company lack a product pipeline to bolster its future product portfolio, then losing exclusivity to any one drug can be a hit to the business.
View narrative
US$173.55
FV
10.6% undervalued intrinsic discount
6.30%
Revenue growth p.a.
14users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
27 days ago author updated this narrative
ST
StjepanK
Equity Analyst and Writer

Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth

Key Takeaways I expect JNJ to remain an established and mature market performer in a relatively stable sector. Some short-term company-related headwinds are cancelled out by long-term industry-related tailwinds Two main risks come from the talc-related litigation issue and patent expiration Most promising revenue growth opportunities are from cancer therapy drugs, with a TAM of $21.6b.
View narrative
US$133.00
FV
16.7% overvalued intrinsic discount
3.00%
Revenue growth p.a.
14users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 months ago author updated this narrative

Johnson & Johnson Competitors

Merck

NYSE:MRK

US$250.9b

Eli Lilly

NYSE:LLY

US$673.5b

Pfizer

NYSE:PFE

US$145.4b

Zoetis

NYSE:ZTS

US$79.8b

Price History & Performance

Summary of all time highs, changes and price drops for Johnson & Johnson
Historical stock prices
Current Share PriceUS$155.17
52 Week HighUS$168.85
52 Week LowUS$143.13
Beta0.52
11 Month Change-3.55%
3 Month Change-5.73%
1 Year Change1.75%
33 Year Change-2.53%
5 Year Change12.86%
Change since IPO24,727.24%

Recent News & Updates

Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive

Nov 19

Johnson & Johnson: Tracking Well Above The Industry

Nov 13

Recent updates

Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive

Nov 19

Johnson & Johnson: Tracking Well Above The Industry

Nov 13

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Oct 19

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Oct 11

Johnson & Johnson: A Sell-Rated Dividend King

Sep 23

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Sep 10
Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Shareholder Returns

JNJUS PharmaceuticalsUS Market
7D0.8%1.6%2.2%
1Y1.8%9.9%31.6%

Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: JNJ underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is JNJ's price volatile compared to industry and market?
JNJ volatility
JNJ Average Weekly Movement1.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: JNJ has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886131,900Joaquin Duatowww.jnj.com

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
JNJ fundamental statistics
Market capUS$373.59b
Earnings (TTM)US$14.77b
Revenue (TTM)US$87.70b

25.3x

P/E Ratio

4.3x

P/S Ratio

Is JNJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNJ income statement (TTM)
RevenueUS$87.70b
Cost of RevenueUS$26.84b
Gross ProfitUS$60.85b
Other ExpensesUS$46.09b
EarningsUS$14.77b

Last Reported Earnings

Sep 29, 2024

Next Earnings Date

Jan 22, 2025

Earnings per share (EPS)6.13
Gross Margin69.39%
Net Profit Margin16.84%
Debt/Equity Ratio51.0%

How did JNJ perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

79%

Payout Ratio

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks
When do you need to buy JNJ by to receive an upcoming dividend?
Johnson & Johnson dividend dates
Ex Dividend DateNov 26 2024
Dividend Pay DateDec 10 2024
Days until Ex dividend1 day
Days until Dividend pay date15 days

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks